版本:
中国

BRIEF-Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083

May 11 Delmar Pharmaceuticals Inc:

* Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083 in recurrent glioblastoma multiforme (gbm)

* Delmar Pharmaceuticals- have resources to initiate phase 3 study of val-083 as single agent treatment for gbm patients who failed both temozolomide & bevacizumab Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐